The administration of urolithin A mitigates barrier dysfunction and colitis development in the mouse model of 2,4,6-trinitrobenzene sulfonic acid-induced colitis; this protective effect is attenuated in mice lacking either Nrf2 or AhR. This evidence concerns the gene AHR and colitis.